PMV Pharma reports FY2022 net loss $73.3M; cash $243.5M; PC14586 update expected 2H 2023

PMV Pharmaceuticals, Inc.

2022-FY EPS reported -$1.61

Net loss $73.3M in FY2022 vs $57.8M in FY2021; R&D expenses rose to $52.0M from $36.5M.
Cash, equivalents, and marketable securities $243.5M at Dec 31, 2022, down from $314.1M.
Phase 1/2 PYNNACLE study of PC14586 ongoing; first patient enrolled in combination arm with KEYTRUDA.
WIP-1 and R273H programs put on hold; projected cash runway extended to 1H 2025.
Appointed Kirsten Flowers and Carol Gallagher to Board; promoted Michael Carulli to SVP Finance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022, was $73.3 million.

Period: the full year ended December 31, 2022
Net income: Net loss for the year ended December 31, 2022, was $73.3 million
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2022, was $73.3 million

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.